Clearpoint Neuro is trading 20.2% down at $12.28 after reporting Q2 results that missed both revenue and earnings estimates and included a full-year 2026 guidance reduction. - The reported revenue of $10.9 million fell short of analyst expectations of approximately $12.73 million. - Investors are reacting to the deeper-than-expected loss per share and the lowered outlook.